Cross-Sector entity

Oxford University

Company
6.5

Of the tracked stories, 1 of 2 also mention Africa Centres for Disease Control and Prevention (Africa CDC), the most common co-covered peer. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 1.5 original sources on average.

2 verified stories tracked

Last mentioned: Jul 27, 2026

RSS updates
Share

Entity pulse

Recent coverage · Oxford University

↑
2 stories
6.5 avg impact
50% positive
50% negative

Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.

  • 50% positive
  • 50% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Oxford University

Of the tracked stories, 1 of 2 also mention Africa Centres for Disease Control and Prevention (Africa CDC), the most common co-covered peer. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 1.5 original sources on average. We currently track 2 Cross-Sector stories that mention Oxford University, published between July 25, 2026 and July 27, 2026.

Stories tracked
2
Sources per story
1.5

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Oxford University. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. 3,000 Cases Milestone

    Total cases reach 3,075, with 1,354 deaths, amid healthcare strikes and calls for accelerated countermeasure development.

  2. First Experimental Vaccine Volunteer Dosed

    Oxford University reports that the first volunteer group has received its candidate vaccine specifically targeting Bundibugyo.

  3. 2,000 Cases Surpassed

    Cumulative confirmed cases exceed 2,000, with rapid spread noted in conflict zones.

  4. WHO reveals outbreak toll

    WHO Director-General announces 1,400+ cases and 438 deaths, confirming the trial's start and expressing hope for effective therapies.

  5. Trial launch and first enrollment

    Researchers begin the first-ever Ebola treatment trial for Bundibugyo virus at Bunia's Evangelical Medical Center, enrolling the first participant to evaluate remdesivir and MBP134.

  6. Outbreak Declared

    DR Congo announces its 17th Ebola outbreak, identifying the Bundibugyo strain as the cause.

Stories mentioning Oxford University 2

Biotech clinical trial Strongly negative 7

Ebola Outbreak Tops 3,000 Cases, Oxford Starts Clinical Trial for Bundibugyo Vaccine

DRC’s 17th Ebola outbreak has exploded to 3,075 cases and 1,354 deaths, with 1,000 new infections in just 10 days. The Bundibugyo strain has no approved vaccine or treatment, igniting a biotech race: Oxford University has dosed its first volunteer with an experimental vaccine, while other candidates are fast-tracked, creating high-stakes opportunities for pharma developers.

2 sources

Source: english.aawsat.com · manilatimes.net